20987 ⎘
Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Hormones Secretins
PRESERVED GIP/GLP AGONIST COMPOSITIONS
#2TIRZEPATIDE COMPOSITIONS AND PREPARATION METHOD
#3GLP-1/GIP DUAL-TARGETED POLYPEPTIDE AND FUSION PROTEIN AND APPLICATIONS THEREOF
#4LONG-ACTING AMYLIN RECEPTOR AGONISTS AND USES THEREOF
#5SWALLOWABLE DRUG DELIVERY DEVICE AND METHODS OF DRUG DELIVERY
#6COMBINATION THERAPY OF INSULINOTROPIC PEPTIDE AND GLP-2, FOR PREVENTING OR TREATING SHORT BOWEL SYNDROME
#7TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS
#8GIP DERIVATIVES AND USES THEREOF
#9METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES
#10GIP/GLP1 CO-AGONIST COMPOUNDS
#11COMPOSITIONS AND METHODS FOR TREATING OBESITY AND HYPERPHAGIA
#12Swallowable drug delivery device and methods of drug delivery
#13Long acting amylin receptor agonists and uses thereof
#14EXOGENOUS PROTEIN-EXPRESSING MICROORGANISM AND USE THEREOF
#15Methods for treatment of COVID-19 syndrome
#16GIP derivatives and uses thereof
#17SAMPLE OBTAINED FROM THE PANCREATIC JUICE AND ANALYSIS THEREOF
#18THERAPEUTIC USE OF GLUCAGON AND COMBINATION INCLUDING THE SAME
#19METHOD TO INDUCE EXFOLIATION OF CELLS AND/OR TISSUE FRAGMENTS FOR ENHANCED CYTOPATHOLOGIC CELL COLLECTION
#20METHOD TO INDUCE EXFOLIATION OF CELLS AND/OR TISSUE FRAGMENTS FOR ENHANCED CYTOPATHOLOGIC CELL COLLECTION
#21Swallowable drug delivery device and methods of drug delivery
#22Compositions and methods for treating obesity and hyperphagia
#23Therapeutic agent preparations into a lumen of the intestinal tract using a swallowable drug delivery device
#24Methods and compositions for treating liver disease
#25GIP derivatives and uses thereof
#26METHODS AND MATERIALS FOR TREATING FUNCTIONAL DYSPEPSIA
#27Therapeutic agent preparations into a lumen of the intestinal tract using a swallowable drug delivery device
#28Swallowable drug delivery device and methods of drug delivery
#29Swallowable drug delivery device and methods of drug delivery
#30Therapeutic agent preparations into a lumen of the intestinal tract using a swallowable drug delivery device
#31Swallowable drug delivery device and method of delivery
#32Method for Treating Pervasive Development Disorders
#33Therapeutic agent preparations into a lumen of the intestinal tract using a swallowable drug delivery device
#34Compositions and methods for treating obesity and hyperphagia
#35METHOD FOR TREATING PERVASIVE DEVELOPMENT DISORDERS
#36Swallowable drug delivery device and methods of drug delivery
#37Method for treating ocular inflammation
#38Peptide Pharmaceutical for Oral Delivery
#39GIP AND GLP-1 RECEPTOR DUAL-AGONISTS FOR THE TREATMENT OF DIABETES
#40Release system of hydrophobic proteins
#41Swallowable drug delivery device and method of delivery
#42Methods for treating pain associated with chronic pancreatitis
#43Method for delivering a therapeutic agent into the wall of the small intestine
#44Method of enhancing diabetes resolution
#45Swallowable drug delivery device and methods of drug delivery
#46Peptide pharmaceutical for oral delivery
#47Peptide pharmaceutical for oral delivery
#48USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH INHIBITORS OF CALCINEURIN OR INHIBITORS OF THE MAMMALIAN TARGET OF RAPAMYCIN (mTOR) COMPLEXES
#49Method for treating pervasive development disorders
#50Method for treating pervasive development disorders
#51Method for treating pervasive development disorders
#52Method for treating pervasive development disorders
#53Peptide pharmaceutical for oral delivery
#54Swallowable drug delivery device and method of delivery
#55Swallowable drug delivery device and methods of drug delivery
#56Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
#57Materials and Methods for Making Improved Micelle Compositions
#58Use of Secretin-Receptor Ligands in Treatment of Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD)
#59Methods of enhancing diabetes resolution
#60USE OF A PEPTIDE AS A THERAPEUTIC AGENT
#61USE OF SECRETIN AND OPTIONALLY URODILATIN AS THERAPEUTIC AGENTS
#62USE OF A PEPTIDE AS A THERAPEUTIC AGENT
#63PROADRENOMEDULLIN ALONE OR IN COMBINATION WITH BIG GASTRIN I AS A THERAPEUTIC AGENT
#64Peptide pharmaceutical for oral delivery
#65Method for identifying individuals having a pervasive development disorder amenable to digestive enzyme therapy
#66Method for identifying autistic individuals amenable to digestive enzyme therapy
#67Method for treating pervasive development disorders
#68Methods of treating pervasive development disorders
#69Use of secretin in treatments of disorders associated with the amygdala
#70Use of secretin in the treatment of schizophrenia
#71Methods for treating diabetes and related disorders using pde10a inhibitors
#72Methods for treating pervasive development disorders
#73Methods for treating pervasive development disorders
#74Use of secretin-receptor ligands in treatment of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD)
#75Methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis
#76Lactone bearing absorbable polymers
#77Method of using secretin and compositions made therefrom for the treatment of autism and other neurological, behavioral and immunological disorders
#78Multipeptide regimen for the treatment of autistic spectrum, behavioral, emotional and visceral inflammation/autoimmune disorders
#79Methods for treatment of acute pancreatitis
#80Materials and methods for making improved micelle compositions
#81Use of secretin and secretin analogs to treat affective disorders